Last reviewed · How we verify
NCT04414631
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Phase 2 trial testing Conestat alfa in Coronavirus Infections in 80 participants. Terminated before completion.
15 September 2021
Quick facts
| Lead sponsor | University Hospital, Basel, Switzerland |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 6 August 2020 |
| Primary completion | 15 September 2021 |
| Estimated completion | 15 September 2021 |
| Sites | 5 locations across Switzerland, Brazil, Mexico |
Drugs / interventions tested
- Conestat alfa (CONESTAT ALFA) — full drug profile →
Conditions studied
- Coronavirus Infections — all drugs for Coronavirus Infections →
Sponsor
University Hospital, Basel, Switzerland
Who can join
Adults 18 to 85, any sex, with Coronavirus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to analyze if administration of conestat alfa for 72 hours in addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) reduces the risk of disease progression to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.
Bonaventura A, Vecchié A, Dagna L, Martinod K, et al · · 2021 · cited 738× · PMID 33824483 · DOI 10.1038/s41577-021-00536-9 -
The state of complement in COVID-19.
Afzali B, Noris M, Lambrecht BN, Kemper C. · · 2022 · cited 224× · PMID 34912108 · DOI 10.1038/s41577-021-00665-1 -
COVID-19: A review of therapeutic strategies and vaccine candidates.
Izda V, Jeffries MA, Sawalha AH. · · 2021 · cited 159× · PMID 33217545 · DOI 10.1016/j.clim.2020.108634 -
The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
Boechat JL, Chora I, Morais A, Delgado L. · · 2021 · cited 139× · PMID 33867315 · DOI 10.1016/j.pulmoe.2021.03.008 -
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System.
Urwyler P, Moser S, Charitos P, Heijnen IAFM, et al · · 2020 · cited 70× · PMID 32922409 · DOI 10.3389/fimmu.2020.02072 -
Complement cascade in severe forms of COVID-19: Recent advances in therapy.
Chouaki Benmansour N, Carvelli J, Vivier E. · · 2021 · cited 51× · PMID 33738806 · DOI 10.1002/eji.202048959 -
The interplay between neutrophils, complement, and microthrombi in COVID-19.
Zuo Y, Kanthi Y, Knight JS, Kim AHJ. · · 2021 · cited 35× · PMID 33526325 · DOI 10.1016/j.berh.2021.101661 -
Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality.
Defendi F, Leroy C, Epaulard O, Clavarino G, et al · · 2021 · cited 32× · PMID 34567008 · DOI 10.3389/fimmu.2021.742446
Verify or expand the search:
- PubMed search for NCT04414631
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronavirus Infections
Currently open trials in the same condition.
- NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
- NCT05276388 — Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19) · active not recruiting
- NCT04429594 — Study of the Incidence of SARS-CoV-2 Infection (COVID-19) · NA · recruiting
- NCT04327570 — In-depth Immunological Investigation of COVID-19. · recruiting
- NCT04318366 — COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor · recruiting
Other University Hospital, Basel, Switzerland trials
Trials by the same sponsor.
- NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
- NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
- NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
- NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
- NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04414631 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
- Last refreshed: 9 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04414631.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing